在计算机模型中开发新型β-分泌酶抑制剂,作为阿尔茨海默病的可能治疗方法
Tassanee Ongtanasup1,2, Komgrit Eawsakul1,3
1Department of Applied Thai Traditional Medicine, School of Medicine, Walailak University, Nakhon Si Thammarat 80160, Thailand.
Advances in pharmacological and pharmaceutical sciences
|April 9, 2025
概括
研究人员发现了一种新型化合物M4,它显示出抑制BACE-1的强大潜力,BACE-1是一种在阿尔茨海默氏症 (AD) 进展中至关重要的酶. 计算机辅助药物设计被用来找到和分析这种有前途的阿尔茨海默氏症治疗候选者.
科学领域:
- 神经科学是一个神经科学.
- 计算化学的计算化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 涉及神经元和轴突的恶化.
- 在AD发病和进展中,β-分泌酶-1 (BACE-1) 酶活性至关重要.
- 在形药物设计有助于识别AD的治疗候选者.
研究的目的:
- 使用计算方法识别BACE-1的新型抑制剂.
- 为选具有与BACE-1活性位点高结合亲和度的化合物.
- 评估已识别的化合物的潜在类似药物的特性和稳定性.
主要方法:
- 开发BACE-1抑制剂的药模型.
- 使用药模型对化合物数据库进行选.
- 分子对接,瑞士ADME分析和分子动力学模拟.
- 使用MMPBSA进行具有约束力的免费能源计算.
主要成果:
- 鉴定ZINC35883784及其衍生品M4与BACE-1具有很高的结合亲和力.
- M4显示与BACE-1具有强烈而稳定的相互作用.
- 瑞士ADME分析表明,M4具有有利的类似药物的特性.
- 预测的NMR和逆合成分析在M4上进行.
结论:
- 作为阿尔茨海默病治疗的BACE-1抑制剂,M4具有显著的潜力.
- 计算方法成功地确定了一个有前途的治疗候选者.
- 需要进一步的实验验证,以确认M4作为BACE-1抑制剂的有效性.
更多相关视频
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
26.5K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.8K
相关概念视频
01:22Alzheimer's Disease: Treatment
133
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
133
01:26Alzheimer's Disease: Overview
342
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
342